Bayer targets mid-20% EBITDA margin and above-market growth by 2029
Bayer says it is targeting above-market growth and a mid-20% CEBITDA margin by 2029, citing progress in margin, sales and cash flow initiatives.
Above-market growth and a mid-20% CEBITDA margin are targeted by 2029, with strong progress on margin, sales, and cash flow initiatives.
Innovation leadership is reinforced by a robust R&D pipeline, digital solutions, and expansion into biologicals and new value pools.Original document: Bayer AG [B…